[{"address1": "1 Commonwealth Lane, No. 08-22", "city": "Singapore", "zip": "149544", "country": "Singapore", "phone": "65 6250 7738", "website": "https://w2.cytomed.sg", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. It has research collaboration agreement with Sengkang General Hospital Pte Ltd to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells (UC-MSCs) to treat cartilage injury. The company was incorporated in 2018 and is headquartered in Singapore.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Chee Kong  Choo", "age": 65, "title": "Executive Chairman", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": 5454, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wee Kiat  Tan Ph.D.", "age": 36, "title": "COO & Director", "yearBorn": 1987, "fiscalYear": 2022, "totalPay": 67442, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jieming  Zeng", "age": 50, "title": "Chief Scientific & Medical Officer and Director", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": 78481, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tien Wee  Luk", "age": 37, "title": "Chief Clinical Officer & Director", "yearBorn": 1986, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yvonne  Goh", "age": 33, "title": "Chief Financial Officer", "yearBorn": 1990, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yoong Ying  Tan", "age": 34, "title": "Chief Corporate Officer", "yearBorn": 1989, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.06, "open": 2.08, "dayLow": 2.06, "dayHigh": 2.13, "regularMarketPreviousClose": 2.06, "regularMarketOpen": 2.08, "regularMarketDayLow": 2.06, "regularMarketDayHigh": 2.13, "forwardPE": -10.349999, "volume": 6473, "regularMarketVolume": 6473, "averageVolume": 56955, "averageVolume10days": 9030, "averageDailyVolume10Day": 9030, "bid": 2.07, "ask": 2.35, "bidSize": 2200, "askSize": 900, "marketCap": 23865650, "fiftyTwoWeekLow": 1.92, "fiftyTwoWeekHigh": 9.25, "priceToSalesTrailing12Months": 41.60729, "fiftyDayAverage": 3.20552, "twoHundredDayAverage": 3.497775, "currency": "USD", "enterpriseValue": 13899251, "floatShares": 1690661, "sharesOutstanding": 11529300, "sharesShort": 19285, "sharesShortPriorMonth": 3288, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0017, "heldPercentInsiders": 0.70795, "heldPercentInstitutions": 0.0008, "shortRatio": 0.35, "shortPercentOfFloat": 0.0045, "impliedSharesOutstanding": 11529300, "bookValue": 1.142, "priceToBook": 1.8126094, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1688083200, "netIncomeToCommon": -4294029, "trailingEps": -0.28, "forwardEps": -0.2, "enterpriseToRevenue": 24.232, "enterpriseToEbitda": -5.236, "52WeekChange": -0.48250002, "SandP52WeekChange": 0.30583346, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GDTC", "underlyingSymbol": "GDTC", "shortName": "CytoMed Therapeutics Limited", "longName": "CytoMed Therapeutics Limited", "firstTradeDateEpochUtc": 1681479000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "5fbb5a07-c64c-3457-b39c-0446de45b69d", "messageBoardId": "finmb_647650276", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.07, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 10437795, "totalCashPerShare": 0.905, "ebitda": -2654634, "totalDebt": 472159, "quickRatio": 36.423, "currentRatio": 36.423, "totalRevenue": 573593, "debtToEquity": 3.585, "revenuePerShare": 0.064, "returnOnAssets": -0.20040001, "returnOnEquity": -0.58314997, "freeCashflow": -1933054, "operatingCashflow": -2947311, "revenueGrowth": 2.813, "grossMargins": 0.98067003, "operatingMargins": -7.14073, "financialCurrency": "SGD", "trailingPegRatio": null}]